GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Change In Payables And Accrued Expense

Alto Neuroscience (Alto Neuroscience) Change In Payables And Accrued Expense : $0.25 Mil (TTM As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Change In Payables And Accrued Expense?

Alto Neuroscience's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was $1.53 Mil. It means Alto Neuroscience's Accounts Payable & Accrued Expense increased by $1.53 Mil from Dec. 2023 to Mar. 2024 .

Alto Neuroscience's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $-0.99 Mil. It means Alto Neuroscience's Accounts Payable & Accrued Expense declined by $0.99 Mil from Dec. 2022 to Dec. 2023 .

Alto Neuroscience Change In Payables And Accrued Expense Historical Data

The historical data trend for Alto Neuroscience's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Change In Payables And Accrued Expense Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
1.10 3.48 -0.99

Alto Neuroscience Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial 0.08 -0.48 - -1.28 1.53

Alto Neuroscience Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.25 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Alto Neuroscience's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
Traded in Other Exchanges
N/A
Address
Website
Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024